181 related articles for article (PubMed ID: 33058427)
1. Loss of TG-Interacting Factor 1 decreases survival in mouse models of myeloid leukaemia.
Yan L; Davé UP; Engel M; Brandt SJ; Hamid R
J Cell Mol Med; 2020 Nov; 24(22):13472-13480. PubMed ID: 33058427
[TBL] [Abstract][Full Text] [Related]
2. Tgif1 regulates quiescence and self-renewal of hematopoietic stem cells.
Yan L; Womack B; Wotton D; Guo Y; Shyr Y; Davé U; Li C; Hiebert S; Brandt S; Hamid R
Mol Cell Biol; 2013 Dec; 33(24):4824-33. PubMed ID: 24100014
[TBL] [Abstract][Full Text] [Related]
3. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
[TBL] [Abstract][Full Text] [Related]
4. Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study.
Farawela HM; Zawam HM; Al-Wakeel HA; El-Nagdy MH; El-Refaey FA; Abdel-Rahman HA
Scand J Clin Lab Invest; 2019; 79(1-2):65-70. PubMed ID: 30638095
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.
Naka K; Hoshii T; Muraguchi T; Tadokoro Y; Ooshio T; Kondo Y; Nakao S; Motoyama N; Hirao A
Nature; 2010 Feb; 463(7281):676-80. PubMed ID: 20130650
[TBL] [Abstract][Full Text] [Related]
7. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.
Vetrie D; Helgason GV; Copland M
Nat Rev Cancer; 2020 Mar; 20(3):158-173. PubMed ID: 31907378
[TBL] [Abstract][Full Text] [Related]
8. HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML.
Li Z; Wang F; Tian X; Long J; Ling B; Zhang W; Xu J; Liang A
J Exp Clin Cancer Res; 2021 Jun; 40(1):210. PubMed ID: 34167558
[TBL] [Abstract][Full Text] [Related]
9. Five year leukaemia-free survival of 72% and 77% for early stage acute and chronic myeloid leukaemia treated by HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K; Dodds A; Concannon A; Milliken S
Aust N Z J Med; 1996 Feb; 26(1):54-8. PubMed ID: 8775529
[TBL] [Abstract][Full Text] [Related]
10. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.
Haladyna JN; Pastuer T; Riedel SS; Perraud AL; Bernt KM
Exp Hematol; 2016 Jul; 44(7):596-602.e3. PubMed ID: 27033163
[TBL] [Abstract][Full Text] [Related]
11. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
12. Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion.
Wang H; Zhang D; Cui X; Dai Y; Wang C; Feng W; Lv X; Li Y; Wang L; Ru Y; Zhang Y; Ren Q; Zheng G
Oncogene; 2022 Apr; 41(16):2303-2314. PubMed ID: 35256780
[TBL] [Abstract][Full Text] [Related]
13. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
15. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.
Liu Q; Chen L; Atkinson JM; Claxton DF; Wang HG
Cell Death Dis; 2016 Sep; 7(9):e2361. PubMed ID: 27607576
[TBL] [Abstract][Full Text] [Related]
16. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
17. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
[TBL] [Abstract][Full Text] [Related]
18. Expression and distribution of aphidicolin-induced fragile sites in chronic myeloid leukaemia, acute lymphocytic leukaemia and acute myeloid leukaemia.
Stopera SA; Ray M
Cytobios; 1989; 60(241):103-9. PubMed ID: 2517248
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Mäkelä E; Pavic K; Varila T; Salmenniemi U; Löyttyniemi E; Nagelli SG; Ammunét T; Kähäri VM; Clark RE; Elo LL; Bachanaboyina VK; Lucas CM; Itälä-Remes M; Westermarck J
Clin Cancer Res; 2021 May; 27(10):2848-2860. PubMed ID: 33674272
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity.
Wu L; Amarachintha S; Xu J; Oley F; Du W
Br J Haematol; 2018 Nov; 183(3):445-456. PubMed ID: 30106181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
